Literature DB >> 9124425

K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock.

A L Salzman1, A Vromen, A Denenberg, C Szabó.   

Abstract

We tested whether activation of K(ATP) channels contributes to vasodilatation and end-organ hypoperfusion in severe hemorrhagic shock (HS). Anesthetized juvenile pigs were hemorrhaged to a portal blood flow of 45% of baseline for 45 min and then resuscitated with Ringer lactate (RL; 100% volume of shed blood; n = 10) or RL in combination with the K(ATP)-channel antagonist glibenclamide (10 mg/kg iv bolus injection; n = 10). Addition of glibenclamide to the resuscitation fluid caused a sustained recovery of systemic blood pressure, cardiac index, portal blood flow, renal blood flow, renal cortical ATP concentration, and ileal mucosal P(CO2). Treatment with RL alone caused only a partial and transient hemodynamic and metabolic benefit. Glibenclamide treatment of sham-shocked control pigs (n = 6) transiently increased mesenteric and systemic vascular resistance. Inhibition of K(ATP)-channel activity in HS, which effectively and safely restores systemic hemodynamics, regional perfusion, and tissue metabolism, is a potentially novel therapeutic approach to the management of severe HS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9124425     DOI: 10.1152/ajpheart.1997.272.2.H688

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Ion channels and the control of blood pressure.

Authors:  E H Baker
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  HMR1402, a potassium ATP channel blocker during hyperdynamic porcine endotoxemia: effects on hepato-splanchnic oxygen exchange and metabolism.

Authors:  Pierre Asfar; Zsolt Iványi; Hendrik Bracht; Balázs Hauser; Antje Pittner; Damian Vassilev; Marek Nalos; Xavier Maurice Leverve; Uwe Bernd Brückner; Peter Radermacher; Gebhard Fröba
Journal:  Intensive Care Med       Date:  2004-03-26       Impact factor: 17.440

Review 3.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

Review 4.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

5.  Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis.

Authors:  Ying-Yuan Pamela Mok; Mohammed Shirhan Bin Mohammed Atan; Cheong Yoke Ping; Wang Zhong Jing; Madhav Bhatia; Shabbir Moochhala; Philip K Moore
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

6.  Early physiologic responses to hemorrhagic hypotension.

Authors:  Ivo P Torres Filho; Luciana N Torres; Roland N Pittman
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

Review 7.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

9.  Mechanisms of direct peritoneal resuscitation-mediated splanchnic hyperperfusion following hemorrhagic shock.

Authors:  El Rasheid Zakaria; Na Li; Richard N Garrison
Journal:  Shock       Date:  2007-04       Impact factor: 3.454

10.  Hyperkalemia accompanies hemorrhagic shock and correlates with mortality.

Authors:  Joel Avancini Rocha Filho; Ricardo Souza Nani; Luiz Augusto Carneiro D'Albuquerque; Carla Augusto Holms; João Plínio Souza Rocha; Luís Marcelo Sá Malbouisson; Marcel Cerqueira César Machado; Maria José Carvalho Carmona; José Otávio Costa Auler Júnior
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.